Pfizer Inc (PFE) Rating Steady Amid Neutral Market Outlook and Pipeline Progress

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Pfizer Inc tops our list for being one of the most undervalued pharmaceutical stocks.

On Friday, December 12, 2025, The Fly reported that Morgan Stanley maintained its Hold (Equal‑Weight) rating on PFE., while lowering the price target to $28 from a prior estimate of $32. The move reflects a neutral outlook on the company’s near-term valuation and growth prospects amid ongoing market pressures.

Pfizer Inc (PFE) Rating Steady Amid Neutral Market Outlook and Pipeline Progress

Piotr Kowalski/Shutterstock.com

The rating followed Pfizer Inc (NYSE:PFE)’s announcement on Wednesday, December 10, 2025, of positive Phase 3 clinical results for its drug TUKYSA (tucatinib). The data showed that adding TUKYSA to first-line maintenance therapy extended median progression-free survival by over eight months in patients with HER2-positive metastatic breast cancer. Acquired through PFE’s Seagen acquisition, TUKYSA highlights the value of the company’s pipeline and acquired assets in offsetting declining COVID-19-related revenues.

Pfizer Inc (NYSE:PFE) is a massive American multinational pharmaceutical and biotechnology corporation. It is known for developing and producing medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.